🇺🇸 FDA
Pipeline program

Imsidolimab

ANB019-002

Phase 2 mab completed

Quick answer

Imsidolimab for Generalized Pustular Psoriasis is a Phase 2 program (mab) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Generalized Pustular Psoriasis
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials